NCT02981966View on ClinicalTrials.gov

Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects

PHASE4CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

May 23, 2019

Primary Completion Date

April 30, 2022

Study Completion Date

May 31, 2023

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Dapagliflozin

dapagliflozin, 10mg tablet

DRUG

Placebo

Placebo for dapagliflozin

Trial Locations (1)

78229

University of Texas Health Science Center, San Antonio

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

lead

The University of Texas Health Science Center at San Antonio

OTHER